Question Bank › Counterparties stepping up before the numbers do

Counterparties stepping up before the numbers do

Counterparties stepping up before the numbers do: escalating committed demand the reported results don't yet show

Calls Tested
492
Answered YES
16
Hit Rate
3.3%
rare by design

Agios Pharmaceuticals, Inc. (AGIO) — this company's answers

NO on the Q3 2018 call 2018-11-01 C
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO based on transcript. Need determine if management describes counterparties paying company currently stepping up commitment beyond prior level, and reported results don't yet reflect because contribution only beginning. Let's parse transcript. Company Agios, TIBSOVO launch. Steve Hoerter commercial update: "Since our launch in July, our team ... approximately 2,000 customer interactions... Increasing testing rates ... key strategic imperative... encouraged with steady growth... market research from August, just after TIBSOVO launched, approximately 80% of physicians were testing... We believe academic centers screening vast majority... community typically behind... focus on improving IDH testing rates among prescribers." "With respect to physician awareness, awareness of TIBSOVO already above 90%, compares favorably to 50% awareness of IDHIFA at similar time in launch. During first two months of TIBSOVO launch, we estimate over 100 unique prescribers have written a prescription... pleased with uptake. Consistent with early IDHIFA experience, expect initial patients treated with TIBSOVO will be more advanced... as launch progresses and patient mix evolves, expect treatment duration to increase. Reimbursement... pleased with payer response... not aware of any payer-related coverage issues. Payer mix... 60% Medicare, 35% commercial, 5% other. This payer split largely consistent with IDHIFA and expected." Question: Does management describe that counterparties who pay company (payers, prescribers? Actually customers are patients/physicians, payers are insurers) are CURRENTLY STEPPING UP their commitment to company in way clearly beyond prior level? And does management convey reported results do not yet meaningfully reflect that step-up because contribution only beginning and mostly still ahead? Need identify if there is a "real escalation by paying counterparties" already happening or committed. The launch of TIBSOVO is new product. But is that a step-up by counterparties? The company just launched a new drug. Physicians prescribing it are new customers. But is that "counterparties moving to distinctly higher level of engagement than they had before"? The company had IDHIFA with Celgene. TIBSOVO is new. The launch itself is new business. But the question asks about paying counterparties stepping up commitment.

← Back to the full AGIO analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the counterparties who pay the company — customers, clients, partners, distributors, payers, or program sponsors — are CURRENTLY STEPPING UP their commitment to the company in a way that goes clearly beyond their prior level of business, AND does management convey that the reported results do not yet meaningfully reflect that step-up, because its contribution is only beginning and mostly still ahead? Answer YES when management's own words convey BOTH halves as one coherent, present-tense story, in whatever form fits the business: (1) A REAL ESCALATION BY PAYING COUNTERPARTIES, ALREADY HAPPENING OR ALREADY COMMITTED. Management describes counterparties moving to a distinctly higher level of engagement than they had before — not merely strong demand in the usual pattern. This may take whatever form fits the industry, for example: customers who started small now committing to substantially larger volumes, broader deployments, more sites, or wider scope; a counterparty moving a relationship from an initial phase into a much bigger committed phase; orders, bookings, or committed work arriving at a scale or pace beyond what the company had been receiving; buyers committing earlier, longer, or bigger than this business has been used to; or new business already won whose delivery ramps ahead. What matters is that the escalation is described as actually occurring or actually committed now — real orders, signed expansions, deliveries beginning, ramps underway — grounded in the behavior of identifiable paying counterparties, not in pipeline, interest, market size, or management's own hopes. (2) THE NUMBERS LAG THE ESCALATION, AND MANAGEMENT SAYS SO. Management conveys, directly or plainly in substance, that the results just reported still mostly reflect the business before this step-up — for example, the larger commitments have only begun converting into revenue, the ramp is early with most delivery ahead, or the company is now preparing, hiring, or building to serve committed business that has not yet flowed through the reported period — so today's numbers understate the business the counterparties have already committed to. Answer NO if the call describes only strong demand, growth, or a good quarter in the company's ordinary rhythm, without counterparties visibly moving to a higher level of commitment than before. NO if the step-up is only hoped for, in negotiation, in pipeline, or dependent on decisions, approvals, or financing not yet obtained. NO if the escalation is a single routine order or renewal of normal size for this business. NO if the increased activity is attributed mainly to a temporary spike, catch-up, pull-forward, or one-time event that management expects to fade. NO if the escalated business is already fully reflected in the reported results with nothing meaningful still to convert. NO if management is chiefly explaining delays, cancellations, or problems with a previously described ramp. NO if the idea appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
OEC Orion Engineered Carbons S.A. Q4 2022 2023-02-17 B+
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
OOMA Ooma, Inc. Q3 2022 2021-12-02 B+
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
KOP Koppers Holdings Inc. Q2 2018 2018-08-12 C+
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
ILMN Illumina, Inc. Q1 2018 2018-04-24 A
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

KOP · Q2 2018 → YESThe question is: Does management describe that counterparties (customers etc.) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that reported results do not yet meaningfully reflect...**NO** The transcript does not describe any counterparties (customers, clients, partners, etc.) currently stepping up their commitment to a distinctly higher level of engagement beyond prior patterns in a way that is already occurring or committed now, with the reported results lagging because most of the benefit is still ahead. The closest item is the major box store converting its ground-contact treated wood program to Koppers’ patented MicroPro technology, planned for late fall with “little effect on the balance of 2018” and a “nice boost heading into 2019.
SCPH · Q3 2023 → YESThe question is: Does management describe that counterparties who pay the company are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully ...YES The transcript shows management describing a clear escalation in payer commitments: a new unrestricted-access agreement with the largest closed IDN (over 8 million lives, fixed copay) and preferred formulary status with a major government retiree payer (adding 1.1 million lives). They explicitly note that direct IDN purchases were not meaningful in Q3 but will be “a meaningful part of our business” moving forward, especially in 2024, and that the new payer decisions “could positively impact FUROSCIX co-pays as early as the fourth quarter.
GFS · Q3 2021 → YESThe question is: Does management describe that counterparties (customers) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully reflect ...**YES** Management describes counterparties (customers) stepping up their commitment through new and expanded long-term agreements (LTAs) and prepayments/access fees, which have grown since the roadshow (from ~$2.5B to north of $3B, with additional $500M+ added post-roadshow) and now exceed $20B in forward revenues. This is framed as real escalation in committed business, with customers signing more agreements and prepaying for future capacity. The reported Q3 results ($1.7B revenue, $0.07 adjusted EPS) and Q4 guidance ($1.

More from the question bank

Escape velocity out of a small baseCash cost of the waitPromise already turning into factMomentum handoff to a young engineCustomers coming back on their ownScheduled future in administrationAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.